Experienced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Jethro Hu

Neurology
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
Offers Telehealth
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jethro Hu is a Neurologist in West Hollywood, California. Dr. Hu is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Torrance Memorial Medical Center
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048
Other Locations
CEDARS-SINAI MEDICAL CARE FOUNDATION
3400 Lomita Blvd, Suite 104, Torrance, CA 90505

Additional Areas of Focus

Dr. Hu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

IIT2016-17-HU-KETORADTMZ: A Phase 1 Study of a 4-month Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Newly/Recently Diagnosed Glioblastoma
IIT2016-17-HU-KETORADTMZ: A Phase 1 Study of a 4-month Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Newly/Recently Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Radiation, Other, Drug
Study Drug: Temozolomide
Study Phase: Phase 1
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: Tozuleristide
Study Phase: Phase 2
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
Enrollment Status: Withdrawn
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Tucatinib, Pembrolizumab, Trastuzumab
Study Phase: Phase 1/Phase 2
Phase I Trial of Vaccination With Autologous Dendritic Cells Pulsed With Lysate Derived From an Allogeneic Glioblastoma Stem-like Cell Line for Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase I Trial of Vaccination With Autologous Dendritic Cells Pulsed With Lysate Derived From an Allogeneic Glioblastoma Stem-like Cell Line for Patients With Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: November 22, 2021
Intervention Type: Biological
Study Drugs: Dendritic cell vaccination+Temozolomide chemotherapy+Involved field radiation therapy, Dendritic cell vaccination+Optional bevacizumab
Study Phase: Phase 1
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
Enrollment Status: Terminated
Publish Date: November 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

30 Total Publications

Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
Journal: BMC medicine
Published: April 25, 2024
Similar Doctors
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Timothy Cloughesy
Neurology | Hematology Oncology
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Timothy Cloughesy
Neurology | Hematology Oncology

The Regents Of The University Of California

100 Medical Plz, Suite 425, 
Los Angeles, CA 
 (3.7 miles away)
310-794-1500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Cloughesy is a Neurologist and a Hematologist Oncology provider in Los Angeles, California. Dr. Cloughesy is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Naveed Wagle
Neurology
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Naveed Wagle
Neurology
2125 Arizona Avenue, Floor 2, 
Santa Monica, CA 
 (6.3 miles away)
310-582-7450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Naveed Wagle is a Neurologist in Santa Monica, California. Dr. Wagle is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliosarcoma. Dr. Wagle is currently accepting new patients.

Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Santosh Kesari
Neurology
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Santosh Kesari
Neurology
2121 Santa Monica Boulevard, 
Santa Monica, CA 
 (6.4 miles away)
310-829-5511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Santosh Kesari is a Neurologist in Santa Monica, California. Dr. Kesari is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy. Dr. Kesari is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile